MACCURA BIOTECHNOLOGY CO.LTD Maccura Biotechnology Co.Ltd Stock
Equities
300463
CNE1000020H3
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.77 CNY | -1.26% |
|
-5.54% | -21.90% |
| Sales 2023 * | 3B 414M | Sales 2024 * | 3.24B 447M | Capitalization | 7.21B 996M |
|---|---|---|---|---|---|
| Net income 2023 * | 321M 44.35M | Net income 2024 * | 477M 65.9M | EV / Sales 2023 * | 2.41 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.23 x |
| P/E ratio 2023 * |
22.6
x | P/E ratio 2024 * |
15.1
x | Employees | 3,016 |
| Yield 2023 * |
1.44% | Yield 2024 * |
2.38% | Free-Float | 61.17% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.26% | ||
| 1 week | -5.54% | ||
| Current month | -7.03% | ||
| 1 month | -14.21% | ||
| 3 months | -12.75% | ||
| 6 months | -20.42% | ||
| Current year | -21.90% |
1 week
11.40
12.48
1 month
11.4013.77
Current year
9.9015.23
1 year
9.9018.18
3 years
9.9049.34
5 years
9.9065.24
10 years
9.9065.24
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Jian Wu
CEO | Chief Executive Officer | 49 | 01-12-31 |
Shan Yin
DFI | Director of Finance/CFO | 44 | 21-10-25 |
Sheng Guo Xu
BRD | Director/Board Member | 46 | 00-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dai Guo Fu
BRD | Director/Board Member | 60 | 19-01-21 |
Yong Tang
CHM | Chairman | 60 | 09-11-21 |
Qi Lin Liu
BRD | Director/Board Member | 57 | 93-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 11.77 | -1.26% | 3,925,619 |
| 24-04-17 | 11.92 | +4.38% | 5,067,200 |
| 24-04-16 | 11.42 | -4.03% | 6,085,800 |
| 24-04-15 | 11.9 | -3.25% | 7,297,087 |
| 24-04-12 | 12.3 | -1.28% | 3,384,400 |
End-of-day quote Shenzhen S.E., April 17, 2024
More quotes
Maccura Biotechnology Co., Ltd., formerly Sichuan Maccura Biotechnology Co., Ltd., is a China-based company principally engaged in research, development, manufacture and sales of in-vitro diagnostics products and the sales of in-vitro diagnostic products of foreign brands as an agent. The Company provides hundreds of products which cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.
Calendar
2024-04-24
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
11.77
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.90% | 996M | |
| -1.59% | 12.47B | |
| -17.62% | 6.99B | |
| -3.93% | 5.1B | |
| -6.68% | 4.27B | |
| +0.53% | 4.27B | |
| -48.27% | 3.45B | |
| +7.09% | 2.61B | |
| -13.71% | 2.08B | |
| -3.40% | 1.67B |
- Stock Market
- Equities
- 300463 Stock
